{"prompt": "['Improving Physical Function in Sarcoma Survivors', 'Protocol number: eIRB# 19942', 'Version # 4.0', '16 APR 2020', 'Pl: Lara Davis, MD', 'TABLE OF CONTENTS', 'SUMMARY OF CHANGES', '2', 'SYNOPSIS', '4', 'SCHEMATIC OF STUDY DESIGN', '7', 'TABLE OF CONTENTS', 'ERROR! BOOKMARK NOT DEFINED.', 'LIST OF TABLES', '11', '1. BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE', '12', '1.1', 'Effects of exercise on post-treatment cancer patients', '12', '1.2', 'Progressive Resistance Training', '12', '1.3', 'Sarcoma and Post-treatment Exercise', '12', '1.4', 'Rationale', '13', '1.5', 'Potential Risks and Benefits.', '13', '1.5.1 Known Potential Risks', '13', '1.5.2 Known Potential Benefits', '14', '2. STUDY OBJECTIVES AND ENDPOINTS', '14', '2.1.1 Primary objective and Endpoint', '14', '2.1.2 Secondary Objectives and Endpoints', '15', '2.1.3 Exploratory Objective and Endpoints', '16', '3. STUDY DESIGN', '16', '3.1', 'Description of the Study Design', '16', '4. STUDY ENROLLMENT AND WITHDRAWAL', '17', '4.1', 'Participant Inclusion Criteria', '17', '4.2', 'Participant Exclusion Criteria', '18', '4.3', 'Strategies for Recruitment and Retention', '18', '4.3.1 Accrual Estimates', '18', '5. STUDY PROCEDURES/EVALUATIONS AND SCHEDULE', '19', '5.1', 'Study Specific Procedures', '19', '5.1.1 Demographics', '19', '5.1.2 Physical limitations', '19', '5.1.3 Adverse event evaluation', '19', '5.1.4 Self-reported Adherence to Assigned Exercise Regimen', '20', '5.1.5 Self-reported Outcome Measures', '20', '8']['Improving Physical Function in Sarcoma Survivors', 'Protocol number: eIRB# 19942', 'Version # 4.0', '16 APR 2020', 'Pl: Lara Davis, MD', '5.1.5.1', 'Godin Leisure-Time Exercise Questionnaire', '20', '5.1.5.2', 'PROMIS-Cancer-Physical Function Measure', '20', '5.1.5.3', '36-Item Short Form Survey', '20', '5.1.5.4', 'FACT-F', '20', '5.1.6 Physical Function Assessments', '20', '5.1.6.1', 'Short Physical Performance Battery (PPB)', '20', '5.1.6.2', 'One-repetition maximum (1RM) Strength Testing', '21', '5.1.6.3', 'Grip Strength.', '21', '5.1.6.4', 'Gait and Balance', '21', '5.1.7 Body Composition and Bone Mineral Density', '21', '5.2', 'Laboratory Procedures and Evaluations', '21', '5.3', 'Screening Assessments', '21', '5.4', 'Baseline Assessments', '22', '5.5', 'Assessments During Treatment', '22', '5.6', 'End of Study Visit and Early Termination Visit', '22', '5.7', 'Unscheduled Visits', '23', '5.8', 'Schedule of Events', '24', '5.8.1 Inclusion of Children', '25', '5.9 OHSU Participant Registration Procedures', '25', '5.10 Participant Screening and Enrollment.', '25', '5.11 Participant Withdrawal or Discontinuation from Study Intervention', '25', '5.11.1 Handling Participant Withdrawal and Discontinuation', '25', '5.12 Criteria for Study Discontinuation', '26', '5.13 Study Suspension or Termination', '26', '6. TREATMENT PLAN', '26', '6.1 Functional Resistance Training Regimen', '26', '6.1.1 In-Person Training Session', '27', '6.1.2 Videoconferencing & Independent Exercise', '28', '6.1.3 End-of-study 3 month follow-up', '28', '6.2 Exercise Modifications', '28', '6.2.1 Exercise delays', '28', '7. EFFICACY MEASURES', '29', '7.1 GLTEQ', '29', '7.2', 'PROMIS-Cancer Physical Function Assessment', '29', '7.3', 'Quality of Life (SF-36)', '29', '7.4', 'Fatigue (FACt-F)', '29', '7.5', 'Short Physical Performance Battery (PPB)', '29', '9']\n\n###\n\n", "completion": "END"}